Invion's expertise and assets target chronic inflammation in two key areas of human health chronic inflammatory airway disease (or respiratory disease), and inflammation caused by autoimmune disease. Invion aims to grow a diverse business with a broad pipeline of drug assets that target better patient outcomes and major commercial opportunities. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States.